Abraham, SM, Lawrence, T, Kleiman, A, Warden, P, Medghalchi, M, Tuckermann, J, Saklatvala, J, and Clark, AR (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203, 1883-1889.
Ali, K, Soond, DR, Pineiro, R, Hagemann, T, Pearce, W, Lim, EL, Bouabe, H, Scudamore, CL, Hancox, T, Maecker, H, Friedman, L, Turner, M, Okkenhaug, K, and Vanhaesebroeck, B (2014). Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 510, 407-411.
Anchoori, RK, Karanam, B, Peng, S, Wang, JW, Jiang, R, Tanno, T, Orlowski, RZ, Matsui, W, Zhao, M, Rudek, MA, Hung, CF, Chen, X, Walters, KJ, and Roden, RB (2013). A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 24, 791-805.
Arguello, F, Alexander, M, Sterry, JA, Tudor, G, Smith, EM, Kalavar, NT, Greene, JF, Koss, W, Morgan, CD, Stinson, SF, Siford, TJ, Alvord, WG, Klabansky, RL, and Sausville, EA (1998). Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood. 91, 2482-2490.
Azoury, SC, Gilmore, RC, and Shukla, V (2016). Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC). Discov. Med. 21, 507-516.
Bauer, R, Udonta, F, Wroblewski, M, Ben-Batalla, I, Santos, IM, Taverna, F, Kuhlencord, M, Gensch, V, Päsler, S, Vinckier, S, Brandner, JM, Pantel, K, Bokemeyer, C, Vogl, T, Roth, J, Carmeliet, P, and Loges, S (2018). Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy. Cancer Res. 78, 3230-3232.
Borriello, F, Iannone, R, and Marone, G (2017). Histamine release from mast cells and basophils. Handb. Exp. Pharmacol. 241, 121-139.
Bu, LL, Yu, GT, Deng, WW, Mao, L, Liu, JF, Ma, SR, Fan, TF, Hall, B, Kulkarni, AB, Zhang, WF, and Sun, ZJ (2016). Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology. 5, e1130206.
Califano, JA, Khan, Z, Noonan, KA, Rudraraju, L, Zhang, Z, Wang, H, Goodman, S, Gourin, CG, Ha, PK, Fakhry, C, Saunders, J, Levine, M, Tang, M, Neuner, G, Richmon, JD, Blanco, R, Agrawal, N, Koch, WM, Marur, S, Weed, DT, Serafini, P, and Borrello, I (2015). Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 30-38.
Cantoni, C, Cignarella, F, Ghezzi, L, Mikesell, B, Bollman, B, Berrien-Elliott, MM, Ireland, AR, Fehniger, TA, Wu, GF, and Piccio, L (2017). Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol. 133, 61-77.
Cao, MD, Xu, YL, Youn, JI, Cabrera, R, Zhang, XK, Gabrilovich, D, Nelson, DR, and Liu, C (2011). Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91, 598-608.
Capuano, G, Rigamonti, N, Grioni, M, Freschi, M, and Bellone, M (2009). Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol. 10, 1.
Cashen, AF, Schiller, GJ, O’Donnell, MR, and DiPersio, JF (2010). Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 28, 556-561.
Chang, CJ, Yang, YH, Chiu, CJ, Lu, LC, Liao, CC, Liang, CW, Hsu, CH, and Cheng, AL (2018). Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int. J. Cancer. 142, 1878-1889.
Changelian, PS, Flanagan, ME, Ball, DJ, Kent, CR, Magnuson, KS, Martin, WH, Rizzuti, BJ, Sawyer, PS, Perry, BD, Brissette, WH, McCurdy, SP, Kudlacz, EM, Conklyn, MJ, Elliott, EA, Koslov, ER, Fisher, MB, Strelevitz, TJ, Yoon, K, Whipple, DA, Sun, J, Munchhof, MJ, Doty, JL, Casavant, JM, Blumenkopf, TA, Hines, M, Brown, MF, Lillie, BM, Subramanyam, C, Shang-Poa, C, Milici, AJ, Beckius, GE, Moyer, JD, Su, C, Woodworth, TG, Gaweco, AS, Beals, CR, Littman, BH, Fisher, DA, Smith, JF, Zagouras, P, Magna, HA, Saltarelli, MJ, Johnson, KS, Nelms, LF, Des Etages, SG, Hayes, LS, Kawabata, TT, Finco-Kent, D, Baker, DL, Larson, M, Si, MS, Paniagua, R, Higgins, J, Holm, B, Reitz, B, Zhou, YJ, Morris, RE, O’Shea, JJ, and Borie, DC (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 302, 875-878.
Chen, J, Deng, CY, Shi, QM, Jiang, J, Zhang, YB, Shan, W, and Sun, WM (2013). CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells. Mol. Med. Rep. 8, 1149-1154.
Chen, S, Huang, A, Chen, H, Yang, Y, Xia, F, Jin, L, and Zhang, J (2016). miR-34a inhibits the apoptosis of MDSCs by suppressing the expression of N-myc. Immunol. Cell Biol. 94, 563-572.
Chen, S, Zhang, Y, Kuzel, TM, and Zhang, B (2015a). Regulating tumor myeloid-derived suppressor cells by microRNAs. Cancer Cell Microenviron. 2, e637.
Chen, SQ, Wang, L, Fan, J, Ye, C, Dominguez, D, Zhang, Y, Curiel, TJ, Fang, DY, Kuzel, TM, and Zhang, B (2015b). Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 75, 519-531.
Cheng, P, Corzo, CA, Luetteke, N, Yu, B, Nagaraj, S, Bui, MM, Ortiz, M, Nacken, W, Sorg, C, Vogl, T, Roth, J, and Gabrilovich, DI (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249.
Clézardin, P, Ebetino, FH, and Fournier, PGJ (2005). Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 65, 4971-4974.
Cushing, TD, Metz, DP, Whittington, DA, and McGee, LR (2012). PI3Kdelta and PI3Kgamma as targets for autoimmune and inflammatory diseases. J. Med. Chem. 55, 8559-8581.
Davis, RJ, Moore, EC, Clavijo, PE, Friedman, J, Cash, H, Chen, Z, Silvin, C, Van Waes, C, and Allen, C (2017). Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3K delta/gamma. Cancer Res. 77, 2607-2619.
Deng, YT, Yang, J, Luo, FF, Qian, J, Liu, RH, Zhang, D, Yu, HX, and Chu, YW (2018). mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells. Cancer Immunol. Immunother. 67, 1355-1364.
Doedens, AL, Stockmann, C, Rubinstein, MP, Liao, D, Zhang, N, DeNardo, DG, Coussens, LM, Karin, M, Goldrath, AW, and Johnson, RS (2010). Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475.
Draghiciu, O, Nijman, HW, Hoogeboom, BN, Meijerhof, T, and Daemen, T (2015). Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology. 4, e989764.
Du Four, S, Maenhout, SK, De Pierre, K, Renmans, D, Niclou, SP, Thielemans, K, Neyns, B, and Aerts, JL (2015). Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology. 4, e998107.
El Gazzar, M (2014). microRNAs as potential regulators of myeloid-derived suppressor cell expansion. Innate Immunity. 20, 227-238.
Engelman, JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer. 9, 550-562.
Eriksson, E, Wenthe, J, Irenaeus, S, Loskog, A, and Ullenhag, G (2016). Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J. Transl. Med. 14, 282.
Espagnolle, N, Barron, P, Mandron, M, Blanc, I, Bonnin, J, Agnel, M, Kerbelec, E, Herault, JP, Savi, P, Bono, F, and Alam, A (2014). Specific inhibition of the VEGFR-3 tyrosine kinase by SAR131675 reduces peripheral and tumor associated immunosuppressive myeloid cells. Cancers (Basel). 6, 472-490.
Finke, J, Ko, J, Rini, B, Rayman, P, Ireland, J, and Cohen, P (2011). MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharm. 11, 856-861.
Flaxenburg, JA, Melter, M, Lapchak, PH, Briscoe, DM, and Pal, S (2004). The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J. Immunol. 172, 7503-7509.
Freston, JW (1982). Cimetidine. I. Developments, pharmacology, and efficacy.. Ann. Intern. Med.. 97, 573-580.
Gabrilovich, DI, and Nagaraj, S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
Gabrilovich, DI, Ostrand-Rosenberg, S, and Bronte, V (2012). Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268.
Ghofrani, HA, Voswinckel, R, Reichenberger, F, Olschewski, H, Haredza, P, Karadas, B, Schermuly, RT, Weissmann, N, Seeger, W, and Grimminger, F (2004). Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. 44, 1488-1496.
Grauers Wiktorin, H, Nilsson, MS, Kiffin, R, Sander, FE, Lenox, B, Rydstrom, A, Hellstrand, K, and Martner, A (2018). Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunol. Immunother. 68, 163-174.
Greenwood, J, Steinman, L, and Zamvil, SS (2006). Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370.
Groth, C, Hu, X, Weber, R, Fleming, V, Altevogt, P, Utikal, J, and Umansky, V (2018). Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer. 120, 16-25.
Guha, P, Gardell, J, Darpolor, J, Cunetta, M, Lima, M, Miller, G, Espat, NJ, Junghans, RP, and Katz, SC (2019). STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene. 38, 533-548.
Guislain, A, Gadiot, J, Kaiser, A, Jordanova, ES, Broeks, A, Sanders, J, van Boven, H, de Gruijl, TD, Haanen, JB, Bex, A, and Blank, CU (2015). Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol. Immunother. 64, 1241-1250.
Guo, X, Qiu, W, Wang, J, Liu, Q, Qian, M, Wang, S, Zhang, Z, Gao, X, Chen, Z, Guo, Q, Xu, J, Xue, H, and Li, G (2018a). Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways. Int. J. Cancer. 144, 3111-3126.
Guo, XF, Qiu, W, Liu, QL, Qian, MY, Wang, SB, Zhang, ZP, Gao, X, Chen, ZH, Xue, H, and Li, G (2018b). Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. Oncogene. 37, 4239-4259.
Hara, E, Smith, R, Parry, D, Tahara, H, Stone, S, and Peters, G (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867.
Hashimoto, A, Gao, C, Mastio, J, Kossenkov, A, Abrams, SI, Purandare, AV, Desilva, H, Wee, S, Hunt, J, Jure-Kunkel, M, and Gabrilovich, DI (2018). Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice. Cancer Res. 78, 5644-5655.
Hegde, VL, Tomar, S, Jackson, A, Rao, R, Yang, X, Singh, UP, Singh, NP, Nagarkatti, PS, and Nagarkatti, M (2013). Distinct microRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by delta9-tetrahydrocannabinol in vivo: regulation of CCAAT/enhancer-binding protein alpha by microRNA-690. J. Biol. Chem. 288, 36810-36826.
Heine, A, Flores, C, Gevensleben, H, Diehl, L, Heikenwalder, M, Ringelhan, M, Janssen, K-P, Nitsche, U, Garbi, N, Brossart, P, Knolle, PA, Kurts, C, and Höchst, B (2017). Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination. Oncoimmunology. 6, e1338995.
Heine, A, Schilling, J, Grünwald, B, Krüger, A, Gevensleben, H, Held, SAE, Garbi, N, Kurts, C, Brossart, P, Knolle, P, Diehl, L, and Höchst, B (2016). The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib. Cancer Immunol. Immunother. 65, 273-282.
Hojjat-Farsangi, M (2014). Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. Int. J. Mol. Sci. 15, 13768-13801.
Hossain, F, Majumder, S, Ucar, DA, Rodriguez, PC, Golde, TE, Minter, LM, Osborne, BA, and Miele, L (2018). Notch signaling in myeloid cells as a regulator of tumor immune responses. Front. Immunol. 9, 1288.
Hou, Y, Feng, Q, Xu, M, Li, GS, Liu, XN, Sheng, Z, Zhou, H, Ma, J, Wei, Y, Sun, YX, Yu, YY, Qiu, JH, Shao, LL, Liu, XG, Hou, M, and Peng, J (2016). High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. Blood. 127, 1587-1597.
Huang, AF, Zhang, HT, Chen, S, Xia, F, Yang, Y, Dong, FL, Sun, D, Xiong, SD, and Zhang, JP (2014). miR-34a expands myeloid-derived suppressor cells via apoptosis inhibition. Exp. Cell Res. 326, 259-266.
Huber, V, Vallacchi, V, Fleming, V, Hu, X, Cova, A, Dugo, M, Shahaj, E, Sulsenti, R, Vergani, E, Filipazzi, P, De Laurentiis, A, Lalli, L, Di Guardo, L, Patuzzo, R, Vergani, B, Casiraghi, E, Cossa, M, Gualeni, A, Bollati, V, Arienti, F, De Braud, F, Mariani, L, Villa, A, Altevogt, P, Umansky, V, Rodolfo, M, and Rivoltini, L (2018). Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505-5516.
Jeon, C, Kang, S, Park, S, Lim, K, Hwang, KW, and Min, H (2011). T cell stimulatory effects of Korean red ginseng through modulation of myeloid-derived suppressor cells. J. Ginseng Res. 35, 462-470.
Köstlin, N, Kugel, H, Spring, B, Leiber, A, Marmé, A, Henes, M, Rieber, N, Hartl, D, Poets, CF, and Gille, C (2014). Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur. J. Immunol. 44, 2582-2591.
Kanasty, R, Dorkin, JR, Vegas, A, and Anderson, D (2013). Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967-977.
Kim, K, Skora, AD, Li, ZB, Liu, Q, Tam, AJ, Blosser, RL, Diaz, LA, Papadopoulos, N, Kinzler, KW, Vogelstein, B, and Zhou, SB (2014). Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U.S.A. 111, 11774-11779.
Kim, SH, Li, M, Trousil, S, Zhang, Y, Pasca di Magliano, M, Swanson, KD, and Zheng, B (2017). Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J. Invest. Dermatol. 137, 1740-1748.
Klinman, DM (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249-259.
Ko, HJ, and Kim, YJ (2016). Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer. Arch. Pharm. Res. 39, 1597-1608.
Ko, JS, Rayman, P, Ireland, J, Swaidani, S, Li, GQ, Bunting, KD, Rini, B, Finke, JH, and Cohen, PA (2010). Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526-3536.
Ko, JS, Zea, AH, Rin, BI, Ireland, JL, Elson, P, Cohen, P, Golshayan, A, Rayman, PA, Wood, L, Garcia, J, Dreicer, R, Bukowski, R, and Finke, JH (2009). Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157.
Kremmyda, L-S, Tvrzicka, E, Stankova, B, and Zak, A (2011). Fatty acids as biocompounds: their role in human metabolism, health and disease: a review. part 2: fatty acid physiological roles and applications in human health and disease.. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.. 155, 195-218.
Kuchen, S, Resch, W, Yamane, A, Kuo, N, Li, Z, Chakraborty, T, Wei, L, Laurence, A, Yasuda, T, Peng, S, Hu-Li, J, Lu, K, Dubois, W, Kitamura, Y, Charles, N, Sun, HW, Muljo, S, Schwartzberg, PL, Paul, WE, O’Shea, J, Rajewsky, K, and Casellas, R (2010). Regulation of microRNA expression and abundance during lymphopoiesis. Immunity. 32, 828-839.
Ledo, AM, Sasso, MS, Bronte, V, Marigo, I, Boyd, BJ, Garcia-Fuentes, M, and Alonso, MJ (2018). Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. J. Control. Release. 295, 60-73.
Lee, BR, Kwon, BE, Hong, EH, Shim, A, Song, JH, Kim, HM, Chang, SY, Kim, YJ, Kweon, MN, Youn, JI, and Ko, HJ (2016). Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells. Cancer Lett. 381, 156-164.
Lei, A, Yang, Q, Li, X, Chen, H, Shi, M, Xiao, Q, Cao, Y, He, Y, and Zhou, J (2016). Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. Immunology. 149, 432-446.
Li, A, Barsoumian, HB, Schoenhals, JE, Cushman, TR, Caetano, MS, Wang, X, Valdecanas, DR, Niknam, S, Younes, AI, Li, G, Woodward, WA, Cortez, MA, and Welsh, JW (2018a). Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 431, 54-63.
Li, J, Yu, S, Ying, J, Shi, T, and Wang, P (2017). Resveratrol prevents ROS-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of AMPK/Sirt1/PGC-1α pathway. Oxid. Med. Cell. Longev. 2017, 7584691.
Li, L, Wang, L, Li, J, Fan, Z, Yang, L, Zhang, Z, Zhang, C, Yue, D, Qin, G, Zhang, T, Li, F, Chen, X, Ping, Y, Wang, D, Gao, Q, He, Q, Huang, L, Li, H, Huang, J, Zhao, X, Xue, W, Sun, Z, Lu, J, Yu, JJ, Zhao, J, Zhang, B, and Zhang, Y (2018b). Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 78, 1779-1791.
Li, L, Zhang, J, Diao, W, Wang, D, Wei, Y, Zhang, CY, and Zen, K (2014). MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J. Immunol. 192, 1034-1043.
Lin, Y, Wang, BS, Shan, W, Tan, YM, Feng, JJ, Xu, L, Wang, LMM, Han, BQ, Zhang, MM, Yu, J, Yu, XH, and Huang, H (2018). mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. Clin. Immunol. 187, 122-131.
Liu, L, Ye, TH, Han, YP, Song, H, Zhang, YK, Xia, Y, Wang, NY, Xiong, Y, Song, XJ, Zhu, YX, Li, DL, Zeng, J, Ran, K, Peng, CT, Wei, YQ, and Yu, LT (2014). Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell. Phys. Biochem. 33, 633-645.
Liu, Q, Zhang, M, Jiang, X, Zhang, Z, Dai, L, Min, S, Wu, X, He, Q, Liu, J, Zhang, Y, Zhang, Z, and Yang, R (2011). miR-223 suppresses differentiation of tumor-induced CD11b(+) Gr1(+) myeloid-derived suppressor cells from bone marrow cells. Int. J. Cancer. 129, 2662-2673.
Liu, Y, Lai, L, Chen, Q, Song, Y, Xu, S, Ma, F, Wang, X, Wang, J, Yu, H, Cao, X, and Wang, Q (2012). MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188, 5500-5510.
Liu, YF, Wei, JY, Shi, MH, Jiang, H, and Zhou, J (2016). Glucocorticoid induces hepatic steatosis by inhibiting activating transcription factor 3 (ATF3)/S100A9 protein signaling in granulocytic myeloid-derived suppressor cells. J. Biol. Chem. 291, 21771-21785.
Liu, YF, Zhuang, KH, Chen, B, Li, PW, Zhou, X, Jiang, H, Zhong, LM, and Liu, FB (2018). Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis. Arthritis Res. Ther. 20, 168.
Long, AH, Highfill, SL, Cui, Y, Smith, JP, Walker, AJ, Ramakrishna, S, El-Etriby, R, Galli, S, Tsokos, MG, Orentas, RJ, and Mackall, CL (2016). Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869-880.
Maenhout, SK, Du Four, S, Corthals, J, Neyns, B, Thielemans, K, and Aerts, JL (2014). AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget. 5, 6801-6815.
Mandelker, D, Gabelli, SB, Schmidt-Kittler, O, Zhu, J, Cheong, I, Huang, CH, Kinzler, KW, Vogelstein, B, and Amzel, LM (2009). A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc. Natl. Acad. Sci. U.S.A. 106, 16996-17001.
Mao, L, Zhao, ZL, Yu, GT, Wu, L, Deng, WW, Li, YC, Liu, JF, Bu, LL, Liu, B, Kulkarni, AB, Zhang, WF, Zhang, L, and Sun, ZJ (2018). γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma. Int. J. Cancer. 142, 999-1009.
Marigo, I, Bosio, E, Solito, S, Mesa, C, Fernandez, A, Dolcetti, L, Ugel, S, Sonda, N, Bicciato, S, Falisi, E, Calabrese, F, Basso, G, Zanovello, P, Cozzi, E, Mandruzzato, S, and Bronte, V (2010). Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. 32, 790-802.
Martin, RK, Saleem, SJ, Folgosa, L, Zellner, HB, Damle, SR, Nguyen, GK, Ryan, JJ, Bear, HD, Irani, AM, and Conrad, DH (2014). Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J. Leukoc. Biol. 96, 151-159.
McClure, C, Brudecki, L, Ferguson, DA, Yao, ZQ, Moorman, JP, McCall, CE, and El Gazzar, M (2014). MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis. Infect. Immun. 82, 3816-3825.
Melani, C, Sangaletti, S, Barazzetta, FM, Werb, Z, and Colombo, MP (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438-11446.
Mikyskova, R, Indrova, M, Vlkova, V, Bieblova, J, Simova, J, Parackova, Z, Pajtasz-Piasecka, E, Rossowska, J, and Reinis, M (2014). DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J. Leukoc. Biol. 95, 743-753.
Moon, YW, Hajjar, J, Hwu, P, and Naing, A (2015). Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J. Immunother. Cancer. 3, 51.
Motzer, RJ, Rini, BI, Bukowski, RM, Curti, BD, George, DJ, Hudes, GR, Redman, BG, Margolin, KA, Merchan, JR, Wilding, G, Ginsberg, MS, Bacik, J, Kim, ST, Baum, CM, and Michaelson, MD (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 295, 2516-2524.
Nakamura, T, Nakao, T, Yoshimura, N, and Ashihara, E (2015). Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells. Am. J. Transplant. 15, 2364-2377.
Nam, S, Kang, K, Cha, JS, Kim, JW, Lee, HG, Kim, Y, Yang, Y, Lee, MS, and Lim, JS (2016). Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. J. Leukoc. Biol. 100, 1273-1284.
Nam, S, Lee, A, Lim, J, and Lim, J-S (2019). Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol. Ther. (Seoul). 27, 63-70.
Nandi, P, Girish, GV, Majumder, M, Xin, X, Tutunea-Fatan, E, and Lala, PK (2017). PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer. 17, 11.
Nefedova, Y, Fishman, M, Sherman, S, Wang, X, Beg, AA, and Gabrilovich, DI (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67, 11021-11028.
Nefedova, Y, Nagaraj, S, Rosenbauer, A, Muro-Cacho, C, Sebti, SM, and Gabrilovich, DI (2005). Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525-9535.
Nishimura, K, Saegusa, J, Matsuki, F, Akashi, K, Kageyama, G, and Morinobu, A (2015). Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice. Arthritis Rheumatol. 67, 893-902.
Noman, MZ, Janji, B, Hu, S, Wu, JC, Martelli, F, Bronte, V, and Chouaib, S (2015). Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res. 75, 3771-3787.
Noonan, KA, Ghosh, N, Rudraraju, L, Bui, M, and Borrello, I (2014). Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol. Res. 2, 725-731.
O’Neill, LAJ, and Hardie, DG (2013). Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 493, 346-355.
Okuma, A, Hanyu, A, Watanabe, S, and Hara, E (2017). p16(Ink4a) and p21(Cip1/Waf1) promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis. Nat. Commun. 8, 2050.
Orillion, A, Hashimoto, A, Damayanti, N, Shen, L, Adelaiye-Ogala, R, Arisa, S, Chintala, S, Ordentlich, P, Kao, C, Elzey, B, Gabrilovich, D, and Pili, R (2017). Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin. Cancer Res. 23, 5187-5201.
Orucevic, A, Bechberger, J, Green, AM, Shapiro, RA, Billiar, TR, and Lala, PK (1999). Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer. 81, 889-896.
Pan, PY, Ma, G, Weber, KJ, Ozao-Choy, J, Wang, G, Yin, B, Divino, CM, and Chen, SH (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70, 99-108.
Pan, T, Zhong, L, Wu, S, Cao, Y, Yang, Q, Cai, Z, Cai, X, Zhao, W, Ma, N, Zhang, W, Zhang, H, and Zhou, J (2016). 17-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)-3 signalling in human pregnancy. Clin. Exp. Immunol. 185, 86-97.
Piazza, F, Manni, S, Ruzzene, M, Pinna, LA, Gurrieri, C, and Semenzato, G (2012). Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia. 26, 1174-1179.
Qin, G, Lian, J, Huang, L, Zhao, Q, Liu, S, Zhang, Z, Chen, X, Yue, D, Li, L, Li, F, Wang, L, Umansky, V, Zhang, B, Yang, S, and Zhang, Y (2018). Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology. 7, e1442167.
Rodriguez, PC, Hernandez, CP, Quiceno, D, Dubinett, SM, Zabaleta, J, Ochoa, JB, Gilbert, J, and Ochoa, AC (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931-939.
Rong, Y, Yuan, CH, Qu, Z, Zhou, H, Guan, Q, Yang, N, Leng, XH, Bu, L, Wu, K, and Wang, FB (2016). Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci. Rep. 6, 23824.
Roskoski, R (2007). Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356, 323-328.
Sawant, A, Schafer, CC, Jin, TH, Zmijewski, J, Tse, HM, Roth, J, Sun, ZH, Siegal, GP, Thannickal, VJ, Grant, SC, Ponnazhagan, S, and Deshane, JS (2013). Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 73, 6609-6620.
Schacke, H, Docke, WD, and Asadullah, K (2002). Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23-43.
Schmid, MC, Avraamides, CJ, Dippold, HC, Franco, I, Foubert, P, Ellies, LG, Acevedo, LM, Manglicmot, JR, Song, X, Wrasidlo, W, Blair, SL, Ginsberg, MH, Cheresh, DA, Hirsch, E, Field, SJ, and Varner, JA (2011). Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 19, 715-727.
Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, and O’Shea, JJ (2017). JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 17, 78.
Scuto, A, Krejci, P, Popplewell, L, Wu, J, Wang, Y, Kujawski, M, Kowolik, C, Xin, H, Chen, L, Wang, Y, Kretzner, L, Yu, H, Wilcox, WR, Yen, Y, Forman, S, and Jove, R (2011). The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 25, 538-550.
Serafini, P, Meckel, K, Kelso, M, Noonan, K, Califano, J, Koch, W, Dolcetti, L, Bronte, V, and Borrello, I (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702.
Setten, RL, Rossi, JJ, and Han, SP (2019). The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18, 421-446.
Shen, L, Orillion, A, and Pili, R (2016). Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. 8, 415-428.
Shi, G, Li, D, Ren, J, Li, X, Wang, T, Dou, H, and Hou, Y (2019). mTOR inhibitor INK128 attenuates dextran sodium sulfate-induced colitis by promotion of MDSCs on Treg cell expansion. J. Cell. Physiol. 234, 1618-1629.
Shirota, Y, Shirota, H, and Klinman, DM (2012). Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 188, 1592-1599.
Singh, UP, Singh, NP, Singh, B, Hofseth, LJ, Taub, DD, Price, RL, Nagarkatti, M, and Nagarkatti, PS (2012). Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(−/−) mice. Brain Behav. Immun. 26, 72-82.
Sinha, P, Clements, VK, Fulton, AM, and Ostrand-Rosenberg, S (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67, 4507-4513.
Sinha, P, Okoro, C, Foell, D, Freeze, HH, Ostrand-Rosenberg, S, and Srikrishna, G (2008). Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675.
Soong, RS, Anchoori, RK, Yang, B, Yang, A, Tseng, SH, He, LM, Tsai, YC, Roden, RBS, and Hung, CF (2016). RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget. 7, 68489-68502.
Suzuki, E (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721.
Tobin, RP, Jordan, KR, Robinson, WA, Davis, D, Borges, VF, Gonzalez, R, Lewis, KD, and McCarter, MD (2018). Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int. Immunopharm. 63, 282-291.
Trikha, P, Plews, RL, Stiff, A, Gautam, S, Hsu, V, Abood, D, Wesolowski, R, Landi, I, Mo, X, Phay, J, Chen, C-S, Byrd, J, Caligiuri, M, Tridandapani, S, and Carson, WE (2016). Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 5, e1214787.
van Hooren, L, Georganaki, M, Huang, H, Mangsbo, SM, and Dimberg, A (2016). Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget. 7, 50277-50289.
Veltman, JD, Lambers, MEH, van Nimwegen, M, Hendriks, RW, Hoogsteden, HC, Aerts, JGJV, and Hegmans, JPJJ (2010). COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.. BMC Cancer. 10, 464.
Vonderheide, RH, and Glennie, MJ (2013). Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043.
Wang, SH, Lu, QY, Guo, YH, Song, YY, Liu, PJ, and Wang, YC (2016). The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur. J. Cancer. 68, 90-105.
Weed, DT, Vella, JL, Reis, IM, De la Fuente, AC, Gomez, C, Sargi, Z, Nazarian, R, Califano, J, Borrello, I, and Serafini, P (2015). Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21, 39-48.
Wei, C, Wang, YX, Ma, L, Wang, X, Chi, H, Zhang, S, Liu, T, Li, ZY, Xiang, DM, Dong, YL, Wu, XG, Shi, WY, and Gao, H (2018). Rapamycin nano-micelle ophthalmic solution reduces corneal allograft rejection by potentiating myeloid-derived suppressor cells’ function. Front. Immunol. 9, 2283.
Winkler, DG, Faia, KL, DiNitto, JP, Ali, JA, White, KF, Brophy, EE, Pink, MM, Proctor, JL, Lussier, J, Martin, CM, Hoyt, JG, Tillotson, B, Murphy, EL, Lim, AR, Thomas, BD, Macdougall, JR, Ren, P, Liu, Y, Li, LS, Jessen, KA, Fritz, CC, Dunbar, JL, Porter, JR, Rommel, C, Palombella, VJ, Changelian, PS, and Kutok, JL (2013). PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364-1374.
Xiao, L, Erb, U, Zhao, K, Hackert, T, and Zöller, M (2017). Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 6, e1319044.
Xu, Z, Ji, JJ, Xu, JJ, Li, D, Shi, GP, Liu, F, Ding, L, Ren, J, Dou, H, Wang, TT, and Hou, YY (2017). MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma. FEBS J. 284, 2410-2424.
Yamaoka, T, Kusumoto, S, Ando, K, Ohba, M, and Ohmori, T (2018). Receptor tyrosine kinase-targeted cancer therapy. Int. J. Mol. Sci. 19, 3491.
Yan, DH, Yang, Q, Shi, MH, Zhong, LM, Wu, CY, Meng, T, Yin, HY, and Zhou, J (2013). Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur. J. Immunol. 43, 2943-2955.
Yoyen-Ermis, D, Ozturk-Atar, K, Kursunel, MA, Aydin, C, Ozkazanc, D, Gurbuz, MU, Uner, A, Tulu, M, Calis, S, and Esendagli, G (2018). Tumor-induced myeloid cells are reduced by gemcitabine-loaded PAMAM dendrimers decorated with anti-Flt1 antibody. Mol. Pharm. 15, 1526-1533.
Yu, H, and Jove, R (2004). The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer. 4, 97-105.
Yun, TK (2001). Brief introduction of Panax ginseng C.A. Meyer. J. Kor. Med. Sci. 16, S3.
Zhang, C, Wang, S, Li, JW, Zhang, WT, Zheng, L, Yang, C, Zhu, TY, and Rong, RM (2017). The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Cell Death Dis. 8, e2695.
Zhang, MM, Liu, QF, Mi, SP, Liang, X, Zhang, ZQ, Su, XM, Liu, JY, Chen, YY, Wang, MM, Zhang, YA, Guo, FH, Zhang, ZJ, and Yang, RC (2011). Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J. Immunol. 186, 4716-4724.
Zhang, S, Wu, K, Liu, Y, Lin, Y, Zhang, X, Zhou, J, Zhang, H, Pan, T, and Fu, Y (2016). Finasteride enhances the generation of human myeloid-derived suppressor cells by up-regulating the COX2/PGE2 pathway. PLoS ONE. 11, e0156549.
Zhang, XH, Fang, XY, Gao, ZZ, Chen, W, Tao, FF, Cai, PF, Yuan, HQ, Shu, YQ, Xu, Q, Sun, Y, and Gu, YH (2014). Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs. 25, 204-211.
Zhao, Y, Shao, Q, Zhu, H, Xu, H, Long, W, Yu, B, Zhou, L, Xu, H, Wu, Y, and Su, Z (2018a). Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability. Cancer Sci. 109, 2677-2686.
Zhao, Y, Shen, XF, Cao, K, Ding, J, Kang, X, Guan, WX, Ding, YT, Liu, BR, and Du, JF (2018b). Dexamethasone-induced myeloid-derived suppressor cells prolong allo cardiac graft survival through iNOS- and glucocorticoid receptor-dependent mechanism. Front. Immunol. 9, 282.
Zheng, YS, Xu, M, Li, X, Jia, JP, Fan, KX, and Lai, GX (2013). Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol. Immunol. 54, 74-83.
Zilio, S, Vella, JL, De la Fuente, AC, Daftarian, PM, Weed, DT, Kaifer, A, Marigo, I, Leone, K, Bronte, V, and Serafini, P (2017). 4PD functionalized dendrimers: a flexible tool for in vivo gene silencing of tumor-educated myeloid cells. J. Immunol. 198, 4166-4177.
Zoglmeier, C, Bauer, H, Noerenberg, D, Wedekind, G, Bittner, P, Sandholzer, N, Rapp, M, Anz, D, Endres, S, and Bourquin, C (2011). CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17, 1765-1775.